Angiomax improves net clinical outcomes

The Medicines Company says that Angiomax (bivalirudin) therapy resulted in improved net adverse clinical outcomes and reduced the risk of major bleeding despite the sex, age, diabetes status or renal function of heart attack patients, according to data from the HORIZONS-AMI trial, which compared the drug to a more complex treatment regimen 30 days following primary angioplasty.

These data, which were presented at the SCAI Annual Scientific Session in Partnership with ACCi2, are consistent with overall results from the HORIZONS-AMI trial that demonstrate treatment with Angiomax resulted in superior net clinical outcomes and fewer cardiac deaths when compared to unfractionated heparin plus a platelet glycoprotein IIb/IIIa inhibitor in ST-segment elevation myocardial infarction, the most severe form of heart attack.